BridgeBio Pharma Analyst Ratings
BridgeBio Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/23/2023 | 125.39% | SVB Leerink | $23 → $19 | Maintains | Outperform |
| 11/18/2022 | 125.39% | JP Morgan | $20 → $19 | Maintains | Overweight |
| 08/24/2022 | 172.84% | Mizuho | $25 → $23 | Maintains | Buy |
| 07/26/2022 | 255.87% | SVB Leerink | $27 → $30 | Maintains | Outperform |
| 05/24/2022 | 125.39% | Goldman Sachs | $24 → $19 | Maintains | Buy |
| 05/06/2022 | 220.28% | SVB Leerink | $26 → $27 | Maintains | Outperform |
| 03/16/2022 | 160.97% | HC Wainwright & Co. | $24 → $22 | Maintains | Buy |
| 03/11/2022 | 113.52% | JP Morgan | $21 → $18 | Maintains | Overweight |
| 03/09/2022 | 208.42% | SVB Leerink | $25 → $26 | Maintains | Outperform |
| 03/04/2022 | 196.56% | SVB Leerink | $24 → $25 | Maintains | Outperform |
| 12/28/2021 | 184.7% | HC Wainwright & Co. | $88 → $24 | Maintains | Buy |
| 12/28/2021 | 184.7% | SVB Leerink | $66 → $24 | Maintains | Outperform |
| 11/19/2021 | 682.92% | SVB Leerink | $68 → $66 | Maintains | Outperform |
| 10/25/2021 | 943.89% | HC Wainwright & Co. | $87 → $88 | Maintains | Buy |
| 10/04/2021 | 706.64% | SVB Leerink | $66 → $68 | Maintains | Outperform |
| 09/10/2021 | 789.68% | B of A Securities | → $75 | Upgrades | Neutral → Buy |
| 08/06/2021 | 682.92% | SVB Leerink | $71 → $66 | Maintains | Outperform |
| 05/21/2021 | 848.99% | UBS | → $80 | Initiates Coverage On | → Buy |
| 05/07/2021 | 848.99% | Goldman Sachs | $92 → $80 | Maintains | Buy |
| 03/23/2021 | 789.68% | SVB Leerink | $67 → $75 | Maintains | Outperform |
| 03/04/2021 | 920.17% | Mizuho | $56 → $86 | Maintains | Buy |
| 02/09/2021 | 884.58% | Goldman Sachs | → $83 | Reinstates | → Buy |
| 01/11/2021 | 932.03% | HC Wainwright & Co. | $64 → $87 | Maintains | Buy |
| 12/10/2020 | 659.19% | HC Wainwright & Co. | $53 → $64 | Maintains | Buy |
| 12/04/2020 | 421.95% | SVB Leerink | $39 → $44 | Maintains | Outperform |
| 10/12/2020 | 528.71% | HC Wainwright & Co. | $50 → $53 | Maintains | Buy |
| 06/25/2020 | 350.77% | B of A Securities | → $38 | Initiates Coverage On | → Neutral |
| 05/19/2020 | 481.26% | BTIG | → $49 | Initiates Coverage On | → Buy |
| 05/14/2020 | 362.63% | SVB Leerink | $41 → $39 | Reiterates | → Outperform |
| 04/13/2020 | 493.12% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 03/03/2020 | 410.08% | JP Morgan | $38 → $43 | Maintains | Overweight |
| 02/19/2020 | 504.98% | Mizuho | → $51 | Initiates Coverage On | → Buy |
| 07/26/2019 | 327.05% | Raymond James | → $36 | Initiates Coverage On | → Outperform |
| 07/22/2019 | 350.77% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
| 07/22/2019 | 350.77% | Jefferies | → $38 | Initiates Coverage On | → Buy |
| 07/22/2019 | 303.32% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
| 07/22/2019 | 398.22% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
| 07/22/2019 | 493.12% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 07/22/2019 | 481.26% | BMO Capital | → $49 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 01/23/2023 | 125.39% | SVB Leerink | $23 → $19 | 维护 | 跑赢大盘 |
| 11/18/2022 | 125.39% | 摩根大通 | $20 → $19 | 维护 | 超重 |
| 08/24/2022 | 172.84% | 瑞穗 | $25 → $23 | 维护 | 买 |
| 07/26/2022 | 255.87% | SVB Leerink | $27 → $30 | 维护 | 跑赢大盘 |
| 05/24/2022 | 125.39% | 高盛 | $24 → $19 | 维护 | 买 |
| 05/06/2022 | 220.28% | SVB Leerink | $26 → $27 | 维护 | 跑赢大盘 |
| 03/16/2022 | 160.97% | HC Wainwright公司 | $24 → $22 | 维护 | 买 |
| 03/11/2022 | 113.52% | 摩根大通 | $21 → $18 | 维护 | 超重 |
| 03/09/2022 | 208.42% | SVB Leerink | $25 → $26 | 维护 | 跑赢大盘 |
| 03/04/2022 | 196.56% | SVB Leerink | $24 → $25 | 维护 | 跑赢大盘 |
| 12/28/2021 | 184.7% | HC Wainwright公司 | $88 → $24 | 维护 | 买 |
| 12/28/2021 | 184.7% | SVB Leerink | $66 → $24 | 维护 | 跑赢大盘 |
| 11/19/2021 | 682.92% | SVB Leerink | $68 → $66 | 维护 | 跑赢大盘 |
| 10/25/2021 | 943.89% | HC Wainwright公司 | $87 → $88 | 维护 | 买 |
| 10/04/2021 | 706.64% | SVB Leerink | $66 → $68 | 维护 | 跑赢大盘 |
| 09/10/2021 | 789.68% | B of A证券 | → $75 | 升级 | 中性→购买 |
| 08/06/2021 | 682.92% | SVB Leerink | $71 → $66 | 维护 | 跑赢大盘 |
| 05/21/2021 | 848.99% | 瑞银集团 | → $80 | 开始承保 | →购买 |
| 05/07/2021 | 848.99% | 高盛 | $92 → $80 | 维护 | 买 |
| 03/23/2021 | 789.68% | SVB Leerink | $67 → $75 | 维护 | 跑赢大盘 |
| 03/04/2021 | 920.17% | 瑞穗 | $56 → $86 | 维护 | 买 |
| 02/09/2021 | 884.58% | 高盛 | → $83 | 恢复 | →购买 |
| 01/11/2021 | 932.03% | HC Wainwright公司 | $64 → $87 | 维护 | 买 |
| 12/10/2020 | 659.19% | HC Wainwright公司 | $53 → $64 | 维护 | 买 |
| 12/04/2020 | 421.95% | SVB Leerink | $39 → $44 | 维护 | 跑赢大盘 |
| 10/12/2020 | 528.71% | HC Wainwright公司 | $50 → $53 | 维护 | 买 |
| 06/25/2020 | 350.77% | B of A证券 | → $38 | 开始承保 | →中性 |
| 05/19/2020 | 481.26% | BTIG | → $49 | 开始承保 | →购买 |
| 05/14/2020 | 362.63% | SVB Leerink | $41 → $39 | 重申 | →跑赢大盘 |
| 04/13/2020 | 493.12% | HC Wainwright公司 | → $50 | 开始承保 | →购买 |
| 03/03/2020 | 410.08% | 摩根大通 | $38 → $43 | 维护 | 超重 |
| 02/19/2020 | 504.98% | 瑞穗 | → $51 | 开始承保 | →购买 |
| 07/26/2019 | 327.05% | 雷蒙德·詹姆斯 | → $36 | 开始承保 | →跑赢大盘 |
| 07/22/2019 | 350.77% | 摩根大通 | → $38 | 开始承保 | →超重 |
| 07/22/2019 | 350.77% | 杰富瑞 | → $38 | 开始承保 | →购买 |
| 07/22/2019 | 303.32% | SVB Leerink | → $34 | 开始承保 | →跑赢大盘 |
| 07/22/2019 | 398.22% | 高盛 | → $42 | 开始承保 | →购买 |
| 07/22/2019 | 493.12% | 派珀·桑德勒 | → $50 | 开始承保 | →超重 |
| 07/22/2019 | 481.26% | 蒙特利尔银行资本 | → $49 | 开始承保 | →跑赢大盘 |
What is the target price for BridgeBio Pharma (BBIO)?
BridgeBio Pharma(BBIO)的目标价是多少？
The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by SVB Leerink on January 23, 2023. The analyst firm set a price target for $19.00 expecting BBIO to rise to within 12 months (a possible 125.39% upside). 10 analyst firms have reported ratings in the last year.
BVB Leerink于2023年1月23日报道了BridgeBio Pharma(纳斯达克：BBIO)的最新目标价。这家分析公司将目标价定为19美元，预计BBIO将在12个月内上涨(涨幅可能为125.39)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
BridgeBio Pharma(BBIO)的最新分析师评级是多少？
The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by SVB Leerink, and BridgeBio Pharma maintained their outperform rating.
对BridgeBio Pharma(纳斯达克：BBIO)的最新分析师评级由SVB Leerink提供，BridgeBio Pharma维持其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
BridgeBio Pharma(BBIO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与BridgeBio Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。BridgeBio Pharma的上一次评级是在2023年1月23日提交的，所以你应该预计下一次评级将在2024年1月23日左右的某个时候提供。
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
分析师对BridgeBio Pharma(BBIO)的评级正确吗？
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $23.00 to $19.00. The current price BridgeBio Pharma (BBIO) is trading at is $8.43, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的BridgeBio Pharma(BBIO)评级维持不变，目标价在23.00美元至19.00美元之间。目前BridgeBio Pharma的交易价格为8.43美元，超出了分析师的预测区间。